A Phase 3 Trial of IMC-F106C (PRAME X CD3) Plus Nivolumab Versus Standard Nivolumab Regimens in HLA-A*02:01+ Patients with Previously Untreated Advanced Melanoma (PRISM-MEL-301).Georgina V. Long,Victoria Atkinson,Paolo A. Ascierto,Diwakar Davar,Omid Hamid,Caroline Robert,Marcus O. Butler,Reinhard Dummer,Christine Hafner,Muhammad A. Khattak,James Larkin,Paul Lorigan,Meredith McKean,Rino S. Seedor,Heather Shaw,Joe Stephenson, Yuan, Roma Patel,Piruntha Thiyagarajah,Dirk SchadendorfJournal of clinical oncology（2024）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
